What is the share price of Rubicon Research Ltd (RUBICON) today?
The share price of RUBICON as on 5th December 2025 is ₹635.80. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Rubicon Research Ltd (RUBICON) share?
The past returns of Rubicon Research Ltd (RUBICON) share are- Past 1 week: -4.11%
- Past 1 month: -4.26%
- Past 3 months: N/A%
- Past 6 months: 1.21%
- Past 1 year: 1.21%
- Past 3 years: N/A%
- Past 5 years: 1.21%
What are the peers or stocks similar to Rubicon Research Ltd (RUBICON)?
The peers or stocks similar to Rubicon Research Ltd (RUBICON) include:What is the dividend yield % of Rubicon Research Ltd (RUBICON) share?
The current dividend yield of Rubicon Research Ltd (RUBICON) is 0.00.What is the market cap of Rubicon Research Ltd (RUBICON) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Rubicon Research Ltd (RUBICON) is ₹10474.82 Cr as of 5th December 2025.What is the 52 week high and low of Rubicon Research Ltd (RUBICON) share?
The 52-week high of Rubicon Research Ltd (RUBICON) is ₹754.80 and the 52-week low is ₹570.75.What is the PE and PB ratio of Rubicon Research Ltd (RUBICON) stock?
The P/E (price-to-earnings) ratio of Rubicon Research Ltd (RUBICON) is 77.96. The P/B (price-to-book) ratio is 19.36.Which sector does Rubicon Research Ltd (RUBICON) belong to?
Rubicon Research Ltd (RUBICON) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Rubicon Research Ltd (RUBICON) shares?
You can directly buy Rubicon Research Ltd (RUBICON) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Rubicon Research Ltd
RUBICON Share Price
635.801.84% (+11.50)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
RUBICON Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
RUBICON Performance & Key Metrics
RUBICON Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 66.63 | 19.36 | 0.00% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.87 | 5.82 | 0.59% |
100%
Analysts have suggested that investors can buy this stock
from 1 analyst
Price Upside
Earnings Growth
Rev. Growth
RUBICON Company Profile
Rubicon Research Ltd is a pharmaceutical formulations company focused on R&D of specialty and drug-device combination products for regulated markets, especially the US, offering multiple dosage forms and therapeutic areas including analgesics, CVS, CNS, gastrointestinal, and respiratory products.
SUNPHARMA
PE Ratio
39.63
39.63
1Y Return
0.45%
0.45%
Buy Reco %
91.67
91.67
TORNTPHARM
PE Ratio
67.04
67.04
1Y Return
12.63%
12.63%
Buy Reco %
76.92
76.92
CIPLA
PE Ratio
23.30
23.30
1Y Return
1.51%
1.51%
Buy Reco %
70.00
70.00
DRREDDY
PE Ratio
18.77
18.77
1Y Return
2.85%
2.85%
Buy Reco %
41.94
41.94
LUPIN
PE Ratio
29.21
29.21
1Y Return
1.24%
1.24%
Buy Reco %
72.22
72.22
RUBICON Sentiment Analysis
RUBICON Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
RUBICON Stock Summary · November 2025
Rubicon Research Limited has successfully transitioned to a product-focused strategy, achieving significant FDA approvals and expanding its presence in regulated markets, particularly the U.S. Despite a decline in gross margins, the company reported impressive year-on-year revenue growth of 39% and improved EBITDA margins, reflecting operational efficiency amidst rising outsourcing costs. The commitment to maintaining R&D expenditure at 10% to 11% of sales supports a diverse product portfolio, with a high commercialization rate indicating effective market strategies. However, manufacturing capacity constraints pose challenges, necessitating reliance on outsourced production until new facilities become operational. Overall, Rubicon's strategic focus on specialty products and compliance underscores its potential for sustained growth and market differentiation.
RUBICON Stock Growth Drivers
RUBICON Stock Growth Drivers
6Strong Foundation and Growth in Pharmaceutical Sector
Rubicon Research Limited has established a solid foundation in the pharmaceutical sector since its inception
Specialty Products and Revenue Growth
In the first half of fiscal 2026, specialty products contributed nearly 33% to Rubicon's total
RUBICON Stock Challenges
RUBICON Stock Challenges
5Declining Contribution from Key Products
The contribution from the top five products decreased to 30%, down from 35% in the
Gross Margin Decline
The company reported a gross margin of 68.7%, reflecting a sequential and year-over-year decline. This
RUBICON Forecast
RUBICON Forecasts
Price
Revenue
Earnings
RUBICON Share Price Forecast
RUBICON Share Price Forecast
2025
Current
₹635.80
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹635.80
Baseline
Forecast for Dec 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
RUBICON Company Revenue Forecast
RUBICON Company Revenue Forecast
2025
Current
₹1.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.30
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
RUBICON Stock EPS (Earnings Per Share) Forecast
RUBICON Stock EPS (Earnings Per Share) Forecast
2025
Current
₹8.78
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹8.78
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
RUBICON
RUBICON
Income
Balance Sheet
Cash Flow
Annual Normal View
RUBICON Income Statement
RUBICON Income Statement
Annual Normal View
| Financial Year | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 281.09 | 324.85 | 330.42 | 419.00 | 872.39 | 1,296.22 | 1,381.62 | |||||||
Raw Materials | 41.92 | 54.52 | 82.13 | 149.40 | 309.33 | 488.95 | 1,081.94 | |||||||
| Power & Fuel Cost | 8.19 | 6.82 | 10.51 | 15.71 | 18.62 | 20.38 | ||||||||
| Employee Cost | 42.91 | 55.82 | 78.90 | 97.12 | 125.34 | 211.05 | ||||||||
| Selling & Administrative Expenses | 66.35 | 83.85 | 130.12 | 104.28 | 223.46 | 344.69 | ||||||||
| Operating & Other expenses | 23.05 | 22.05 | 51.13 | 8.53 | 22.54 | -36.74 | ||||||||
EBITDA | 98.67 | 101.79 | -22.37 | 43.96 | 173.10 | 267.89 | 299.68 | |||||||
| Depreciation/Amortization | 18.45 | 29.31 | 34.01 | 36.06 | 38.97 | 36.59 | 38.95 | |||||||
| PBIT | 80.22 | 72.48 | -56.38 | 7.90 | 134.13 | 231.30 | 260.73 | |||||||
| Interest & Other Items | 6.20 | 9.37 | 9.72 | 18.96 | 31.26 | 36.78 | 39.15 | |||||||
| PBT | 74.02 | 63.11 | -66.10 | -11.06 | 102.87 | 194.52 | 221.58 | |||||||
| Taxes & Other Items | 24.60 | 32.43 | 1.01 | 5.84 | 11.85 | 60.16 | 64.38 | |||||||
| Net Income | 49.42 | 30.68 | -67.11 | -16.90 | 91.02 | 134.36 | 157.20 | |||||||
| EPS | 3.25 | 2.02 | -4.41 | -1.11 | 5.98 | 8.78 | 10.20 | |||||||
| DPS | 0.07 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | |||||||
| Payout ratio | 0.02 | 0.02 | — | — | 0.00 | 0.00 | 0.00 |
RUBICON Company Updates
FY 2026FY 2026
Investor Presentation
Nov 13PDF
RUBICON Stock Peers
RUBICON Past Performance & Peer Comparison
RUBICON Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Rubicon Research Ltd | 77.96 | 19.36 | 0.00% |
| Sun Pharmaceutical Industries Ltd | 39.63 | 5.98 | 0.89% |
| Torrent Pharmaceuticals Ltd | 67.04 | 16.88 | 0.85% |
| Cipla Ltd | 23.30 | 3.93 | 1.05% |
RUBICON Stock Price Comparison
Compare RUBICON with any stock or ETFCompare RUBICON with any stock or ETF
RUBICON
RUBICON Holdings
RUBICON Shareholdings
RUBICON Promoter Holdings Trend
RUBICON Promoter Holdings Trend
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
RUBICON Institutional Holdings Trend
RUBICON Institutional Holdings Trend
No institutional holdings trend are available
RUBICON Shareholding Pattern
RUBICON Shareholding Pattern
RUBICON Shareholding History
RUBICON Shareholding History
Foreign Institutions
Mutual Funds Invested in RUBICON
Mutual Funds Invested in RUBICON
No mutual funds holding trends are available
Top 5 Mutual Funds holding Rubicon Research Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.9920% | Percentage of the fund’s portfolio invested in the stock 0.35% | Change in the portfolio weight of the stock over the last 3 months 0.35% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 68/71 (+2) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3264% | Percentage of the fund’s portfolio invested in the stock 2.38% | Change in the portfolio weight of the stock over the last 3 months 2.38% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 35/64 (+29) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4733% | Percentage of the fund’s portfolio invested in the stock 1.90% | Change in the portfolio weight of the stock over the last 3 months 1.90% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 41/68 (+27) |
Compare 3-month MF holding change on Screener
smallcases containing RUBICON stock
smallcases containing RUBICON stock
Looks like this stock is not in any smallcase yet.
RUBICON Events
RUBICON Events
RUBICON Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.00%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.03 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
RUBICON Dividend Trend
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.00%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.03 every year
RUBICON Dividends
RUBICON Dividends
Hmm, looks like data is unavailable here. Please come back after some timeRUBICON Stock News & Opinions
RUBICON Stock News & Opinions
Articles & Videos
Earnings
Rubicon Research consolidated net profit rises 56.18% in the September 2025 quarter
Net profit of Rubicon Research rose 56.18% to Rs 53.85 crore in the quarter ended September 2025 as against Rs 34.48 crore during the previous quarter ended September 2024. Sales rose 39.19% to Rs 412.02 crore in the quarter ended September 2025 as against Rs 296.01 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales412.02296.01 39 OPM %22.8820.83 - PBDT83.5857.30 46 PBT71.7149.15 46 NP53.8534.48 56 Powered by Capital Market - Live
3 weeks agoCapital Market - Live
Corporate
Rubicon Research to convene board meeting
Rubicon Research will hold a meeting of the Board of Directors of the Company on 13 November 2025.Powered by Capital Market - Live
4 weeks agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 35.76%, vs industry avg of 10.04%
Over the last 5 years, market share increased from 0.11% to 0.31%
Over the last 5 years, net income has grown at a yearly rate of 22.14%, vs industry avg of 20.02%